403 related articles for article (PubMed ID: 11718560)
21. Delineation of the domains required for physical and functional interaction of p14ARF with human topoisomerase I.
Ayrault O; Karayan L; Riou JF; Larsen CJ; Séité P
Oncogene; 2003 Apr; 22(13):1945-54. PubMed ID: 12673200
[TBL] [Abstract][Full Text] [Related]
22. An N-terminal p14ARF peptide blocks Mdm2-dependent ubiquitination in vitro and can activate p53 in vivo.
Midgley CA; Desterro JM; Saville MK; Howard S; Sparks A; Hay RT; Lane DP
Oncogene; 2000 May; 19(19):2312-23. PubMed ID: 10822382
[TBL] [Abstract][Full Text] [Related]
23. Nucleolar Arf tumor suppressor inhibits ribosomal RNA processing.
Sugimoto M; Kuo ML; Roussel MF; Sherr CJ
Mol Cell; 2003 Feb; 11(2):415-24. PubMed ID: 12620229
[TBL] [Abstract][Full Text] [Related]
24. Mdm2 regulates p53 independently of p19(ARF) in homeostatic tissues.
O'Leary KA; Mendrysa SM; Vaccaro A; Perry ME
Mol Cell Biol; 2004 Jan; 24(1):186-91. PubMed ID: 14673154
[TBL] [Abstract][Full Text] [Related]
25. p14ARF expression in invasive breast cancers and ductal carcinoma in situ--relationships to p53 and Hdm2.
Vestey SB; Sen C; Calder CJ; Perks CM; Pignatelli M; Winters ZE
Breast Cancer Res; 2004; 6(5):R571-85. PubMed ID: 15318938
[TBL] [Abstract][Full Text] [Related]
26. The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2.
Stott FJ; Bates S; James MC; McConnell BB; Starborg M; Brookes S; Palmero I; Ryan K; Hara E; Vousden KH; Peters G
EMBO J; 1998 Sep; 17(17):5001-14. PubMed ID: 9724636
[TBL] [Abstract][Full Text] [Related]
27. Identification of a novel nucleophosmin-interaction motif in the tumor suppressor p14arf.
Luchinat E; Chiarella S; Franceschini M; Di Matteo A; Brunori M; Banci L; Federici L
FEBS J; 2018 Mar; 285(5):832-847. PubMed ID: 29283500
[TBL] [Abstract][Full Text] [Related]
28. p53 apoptotic pathway molecules are frequently and simultaneously altered in nonsmall cell lung carcinoma.
Mori S; Ito G; Usami N; Yoshioka H; Ueda Y; Kodama Y; Takahashi M; Fong KM; Shimokata K; Sekido Y
Cancer; 2004 Apr; 100(8):1673-82. PubMed ID: 15073856
[TBL] [Abstract][Full Text] [Related]
29. Growth suppression by a p14(ARF) exon 1beta adenovirus in human tumor cell lines of varying p53 and Rb status.
Saadatmandi N; Tyler T; Huang Y; Haghighi A; Frost G; Borgstrom P; Gjerset RA
Cancer Gene Ther; 2002 Oct; 9(10):830-9. PubMed ID: 12224024
[TBL] [Abstract][Full Text] [Related]
30. p14(ARF) regulates E2F activity.
Mason SL; Loughran O; La Thangue NB
Oncogene; 2002 Jun; 21(27):4220-30. PubMed ID: 12082609
[TBL] [Abstract][Full Text] [Related]
31. Deregulation of the TP53/p14ARF tumor suppressor pathway in low-grade diffuse astrocytomas and its influence on clinical course.
Watanabe T; Katayama Y; Yoshino A; Komine C; Yokoyama T
Clin Cancer Res; 2003 Oct; 9(13):4884-90. PubMed ID: 14581362
[TBL] [Abstract][Full Text] [Related]
32. ARF tumor suppression in the nucleolus.
Maggi LB; Winkeler CL; Miceli AP; Apicelli AJ; Brady SN; Kuchenreuther MJ; Weber JD
Biochim Biophys Acta; 2014 Jun; 1842(6):831-9. PubMed ID: 24525025
[TBL] [Abstract][Full Text] [Related]
33. p14ARF interacts with N-Myc and inhibits its transcriptional activity.
Amente S; Gargano B; Diolaiti D; Della Valle G; Lania L; Majello B
FEBS Lett; 2007 Mar; 581(5):821-5. PubMed ID: 17289033
[TBL] [Abstract][Full Text] [Related]
34. CARF (collaborator of ARF) interacts with HDM2: evidence for a novel regulatory feedback regulation of CARF-p53-HDM2-p21WAF1 pathway.
Hasan MK; Yaguchi T; Harada JI; Hirano T; Wadhwa R; Kaul SC
Int J Oncol; 2008 Mar; 32(3):663-71. PubMed ID: 18292944
[TBL] [Abstract][Full Text] [Related]
35. MdmX inhibits ARF mediated Mdm2 sumoylation.
Ghosh M; Weghorst K; Berberich SJ
Cell Cycle; 2005 Apr; 4(4):604-8. PubMed ID: 15876864
[TBL] [Abstract][Full Text] [Related]
36. Molecular characterization of the hdm2-p53 interaction.
Böttger A; Böttger V; Garcia-Echeverria C; Chène P; Hochkeppel HK; Sampson W; Ang K; Howard SF; Picksley SM; Lane DP
J Mol Biol; 1997 Jun; 269(5):744-56. PubMed ID: 9223638
[TBL] [Abstract][Full Text] [Related]
37. Further insight into substrate recognition by USP7: structural and biochemical analysis of the HdmX and Hdm2 interactions with USP7.
Sarkari F; La Delfa A; Arrowsmith CH; Frappier L; Sheng Y; Saridakis V
J Mol Biol; 2010 Oct; 402(5):825-37. PubMed ID: 20713061
[TBL] [Abstract][Full Text] [Related]
38. ARF-BP1/Mule is a critical mediator of the ARF tumor suppressor.
Chen D; Kon N; Li M; Zhang W; Qin J; Gu W
Cell; 2005 Jul; 121(7):1071-83. PubMed ID: 15989956
[TBL] [Abstract][Full Text] [Related]
39. Multiple sites of in vivo phosphorylation in the MDM2 oncoprotein cluster within two important functional domains.
Hay TJ; Meek DW
FEBS Lett; 2000 Jul; 478(1-2):183-6. PubMed ID: 10922493
[TBL] [Abstract][Full Text] [Related]
40. Functional and physical interactions of the ARF tumor suppressor with p53 and Mdm2.
Kamijo T; Weber JD; Zambetti G; Zindy F; Roussel MF; Sherr CJ
Proc Natl Acad Sci U S A; 1998 Jul; 95(14):8292-7. PubMed ID: 9653180
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
